Discover
ELVN
Enliven Therapeutics, Inc.
49.45
2 x 36.36
2 x 63.78
bid
ask
-
0.79
1.57%
2 @ 04:03 AM
49.35 -0.10 (0.20%)
| Ytd | 221.10% | |
| 1y | 148.24% |
49.20
day range
51.20
14.79
52 week range
62.32
| Open | 49.43 | Prev Close | 50.24 | Low | 49.20 | High | 51.20 | Mkt Cap | 3.62B |
| Vol | 6.01M | Avg Vol | 1.29M | EPS | -1.65 | P/E | N/A | Forward P/E | -21.15 |
| Beta | 0.24 | Short Ratio | 8.31 | Inst. Own | 113.91% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 56.26 | 200-d Avg | 39.08 | 1yr Est | 73.90 |
ELVN News
seekingalpha.com
Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conferenc
Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conferenc
benzinga.com
Reported Earlier, Enliven To Present New ELVN-001 Blood Cancer Trial Data At September Medical Meeti
Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutica